Hively Brad sold $1.9M of STLN
Hively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, potentially influencing short‑term sentiment.
Market read
Primary source insider sale; modest relevance for traders monitoring STLN.
What to watch
Sale executed under pre‑arranged 10b5‑1 plan, reducing signaling strength.
Background
Form 4 filing discloses insider transactions; provides transparent data for market participants.
Ticker impact
Director Brad Hively sold 298,853 shares for $1.95M via a 10b5‑1 plan, reducing his stake to 411,976 shares.
Potential modest decline in near‑term trading range.
Director insider sales often weigh on investor perception, especially when sizable relative to float.
Market effects
Minimal impact on oncology sector; isolated to Starling Oncology.
None
None
Counterpoint
Insider may be diversifying; sale does not necessarily reflect company fundamentals.
Key entities
- CompanyStarling Oncology, Inc.
Biotech firm listed on NASDAQ under ticker STLN.
- InsiderBrad Hively
Director of Starling Oncology executing a 10b5‑1 sale.